Replies to post #130335 on Biotech Values

[DewDiligence]

[DEB025] could find a market after years of nuke/riba or nuke monotherapy but I would expect this to be very limited.

Why would DEB025 have to be relegated to the second- or third-line setting? If it can add modest efficacy to a nuke-based regimen with no increase in resistance, I see no reason why DEB025 is unsuited to the first-line setting.